Junius will head ImmunoGen

ImmunoGen Inc. of Waltham said today that president and chief operating officer Daniel M. Junius will become president and chief executive, effective Jan. 1.

The promotion of Junius is in accordance with a succession plan approved by ImmunoGen's board of directors, said the company, which added that Junius has also been nominated for election to the company's board at the company's annual shareholders meeting.

Current chairman and chief executive Mitchel Sayare will continue as the chairman of the board and as a director of the company, ImmunoGen said.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies, and the creation and attachment of potent cell-killing agents.
(By Chris Reidy, Globe staff)